A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS
Study of RO7198457 in locally advanced or metastatic tumors
Sponsor: Genentech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR5625
U.S. Govt. ID: NCT03289962
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if the study treatment called RO7198457 (PCV) can be safely given to patients with cancer. PCV is a personalized cancer vaccine. Participants will either received PCV alone or in combination with atezolizumab.
This study is closed
Investigator
Brian Henick, MD
Do You Qualify?
Do you have confirmed cancer? Yes No
Have you received treatment for your cancer or have a disease that does not have standard therapy? Yes No
Are you able to walk, care for yourself, and do light physical activities? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE